logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.

    • Medications for Macular Edema Due To Diabetes Mellitus

    FiltersReset Filters
    10 results

    • ahzantive

      (aflibercept-mrbb)
      Valorum Biologics Inc
      Usage: AHZANTIVE is indicated for the treatment of neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy.

    • beovu

      (brolucizumab)
      Novartis Pharmaceuticals Corporation
      Usage: BEOVU® is indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME).

    • cimerli

      (ranibizumab-eqrn)
      Coherus BioSciences Inc
      Usage: CIMERLI is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.

    • eylea

      (aflibercept)
      Regeneron Pharmaceuticals, Inc.
      Usage: EYLEA is indicated for treating neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity.

    • eylea hd

      (aflibercept)
      Regeneron Pharmaceuticals, Inc
      Usage: EYLEA HD is indicated for the treatment of neovascular (wet) age-related macular degeneration, diabetic macular edema, and diabetic retinopathy.

    • iluvien

      (fluocinolone acetonide)
      Alimera Sciences, Inc.
      Usage: ILUVIEN® is indicated for the treatment of diabetic macular edema (DME) in patients previously treated with corticosteroids without significant intraocular pressure increase, and for chronic non-infectious uveitis affecting the posterior segment of the eye.

    • lucentis

      (RANIBIZUMAB)
      Genentech, Inc.
      Usage: LUCENTIS is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR), and myopic choroidal neovascularization (mCNV).

    • ozurdex

      (dexamethasone)
      Allergan, Inc.
      Usage: OZURDEX (dexamethasone intravitreal implant) is indicated for treating macular edema due to branch or central retinal vein occlusion, non-infectious uveitis affecting the posterior segment of the eye, and diabetic macular edema.

    • susvimo

      (Ranibizumab)
      Genentech, Inc.
      Usage: SUSVIMO (ranibizumab injection) is indicated for treating Neovascular (wet) Age-related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR) in patients who have previously responded to at least two intravitreal injections of a Vascular Endothelial Growth Factor (VEGF) inhibitor.

    • vabysmo

      (Faricimab)
      Genentech, Inc.
      Usage: VABYSMO is indicated for treating patients with neovascular (wet) age-related macular degeneration (nAMD), diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO). It acts as a VEGF and angiopoietin 2 (Ang-2) inhibitor.